DUBLIN, Ireland - (Business Wire) Research and Markets (
http://www.researchandmarkets.com/reports/c86315) has announced the addition of
“Peru Pharmaceuticals and Healthcare Report Q1 2008
” to their offering.
The Peru Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Peru's pharmaceuticals and healthcare industry.
Peru’s pharmaceutical market remains small in relative terms - standing at an estimated US$666mn in 2007. Per capita drug expenditure is just US$23.1 due to a preference for cheap, non-equivalent branded generics called ‘similares’. The market is forecast to reach US$850mn by 2012, representing a CAGR of just 5%. We expect the generics market in particular to exhibit strong growth as the implementation of a free trade agreement (FTA) with the US leads to a tougher stance on similares that should push patients towards legitimate generics.
In December 2007, the Peru-US free trade agreement was finally signed by US President George Bush and Peruvian President Alan García following its ratification by the US Congress in the previous month. Although the wording of the intellectual property (IP) right provisions in the bill were watered-down under pressure from the Democrat-controlled US Congress, the agreement should still allow the vast majority of US exports duty-free access to Peru. Consequently, it is the US generics industry that has made the most positive noises concerning the bill. Overall trade between the two countries reached US$9bn in 2006.
For Q108, BMI has overhauled its Business Environment Ratings methodology. Under the new system, Peru is ranked last in the Americas regions on 39 points, just one point behind Venezuela. The small size of the drug market and unspectacular growth forecast serve to limit the potential returns. However, in terms of risk, the market is mid-ranking in the region due to an improving regulatory environment and stable political and economic environment.
The government’s 2008 budget, published in August, pledges a 28% increase in overall investment, with social services seeing steep rises. Higher tax revenues and a booming economy should allow continuing record budget surpluses. This should help García push forward increased coverage under the unified and strengthened Seguro Integral de Salud (SIS) health insurance system. The key will be ensuring those newly enrolled in the scheme can actually access health services and obtain basic medicine. Opposition parties are questioning the view that García handled the August 2007 earthquake and resulting health crisis admirably, citing HIV-infected blood transfusions and irregular health purchases that could see citizens returning to street protests.
Contents:
Executive Summary
Peru: Pharmaceuticals and Healthcare Industry SWOT
Peru Political SWOT Analysis
Peru Economic SWOT Analysis
Peru Business Environment SWOT Analysis
Business Environment Ranking
Pharmaceutical Ratings - Revised Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Component
Peru - Business Environment Ranking
Table: Pharmaceutical Business Environment Rankings
Limits To Potential Returns
Risks To Realisation Of Returns
Peru - Market Summary
Regulatory Regime
Intellectual Property Regime
Pricing And Reimbursement Issues
Other Regulatory Issues
Industry Developments
Healthcare Sector
Pharmaceutical Sector
Industry Forecast Sce
Overall Market Forecast
Table: Peru Drug Market Indicators, 2006-2012
Key Growth Factors - Industry
Table: Health Expenditure Indicators
Key Growth Factors - Macroeconomic
Table: Peru - Economic Activity
Prescription Market Forecast
Table: Prescription Market Indicators (US$mn unless otherwise stated)
OTC Market Forecast
Table: OTC Market Indicators (US$mn unless otherwise stated)
Generics Market Forecast
Table: Generic Market Indicators
Export/Import Forecasts
Table: Import/Export Trends (US$mn)
Other Healthcare Data Forecasts
Table: Other Healthcare Data Forecasts
Key Risks to BMI’s Forecast Scenario
Competitive Landscape
Peru Pharmaceuticals & Healthcare Report Q1 2008
Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006
Company Profiles
Leading Multinationals
Sanofi-Aventis
Merck & Co
GlaxoSmithKline
Novartis
Pfizer
Indigenous Manufacturer Profiles
Farmaindustria
Unimed
Our Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources
For more information visit http://www.researchandmarkets.com/reports/c86315
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
